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SUMMARY 1 
In contemporary international guidelines on the management of atrial fibrillation, 2 
there is general agreement about the baseline evaluation of thromboembolic and 3 
bleeding risk and preferential use of NOACs. Notwithstanding the broad agreement, 4 
more data are needed about management of specific AF sub-populations. The need 5 
for an integrated approach and holistic management is highlighted in the more 6 
recently published guidelines.  7 
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ABSTRACT 1 
In recent years the management of AF patients has progressively and substantially 2 
changed due to the introduction of new treatments and the availability of new data 3 
regarding the epidemiology and clinical management of these patients. In the last 4 
two years alone, there have been seven new guidelines or guideline updates that 5 
have been published, introducing new recommendations and significantly revising 6 
previously published ones. Two updates for Canadian guidelines were published in 7 
2016 and 2018, while guidelines from the European Society of Cardiology in 2016, 8 
Asia Pacific Heart Rhythm Society in 2017, National Heart Foundation of 9 
Australia/Cardiac Society of Australia and New Zealand, American College of Chest 10 
Physicians and Korean Heart Rhythm Society in 2018 have been published. This 11 
narrative review aims to provide a comparison of these contemporary international 12 
guidelines, with particular attention on the evaluation of thromboembolic and 13 
bleeding risks and management of OAC therapy.  14 
From the analysis of contemporary guidelines on the management of atrial 15 
fibrillation, a general agreement is evident about the baseline evaluation of 16 
thromboembolic and bleeding risk, as well as a preference for the use of NOACs. 17 
Also, regarding the concomitant use of OAC and antiplatelet drugs in patients with 18 
acute coronary syndromes, undergoing elective percutaneous coronary intervention, 19 
catheter ablation and cardioversion procedures, all the guidelines agree on the 20 
general principles and are supported by evidence. More data are still needed to 21 
better substantiate recommendations for specific AF sub-populations. The need for 22 
an integrated approach and holistic management is highlighted in the more recently 23 
published guidelines. 24 
 25 
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Introduction 1 
In the last ten years, clinical practice on stroke prevention in patients with atrial 2 
fibrillation (AF) has markedly changed1. The introduction of non-vitamin K antagonist 3 
oral anticoagulants (NOACs) as an alternative to the vitamin K antagonists (VKAs)2, 4 
has significantly increased the prescription and use of oral anticoagulant (OAC) 5 
therapy in AF patients, as demonstrated by several epidemiological and 6 
observational studies3–6. 7 
 8 
There has been much interest in expanding the understanding of AF 9 
pathophysiology, epidemiology and natural history, leading to an increasing number 10 
of papers on AF being published [Figure 1]. The deluge of data available has 11 
informed how several new issues are managed and have led to a change in clinical 12 
practice regarding patients with AF, both regarding the evaluation and reduction of 13 
thromboembolic risk as well as the general management of such patients. There is 14 
also an increasing focus on how the risk of cardiovascular and all-cause death is 15 
becoming an even more relevant issue in clinical history and clinical management of 16 
these patients7–10. This change in the risk profile has led to appeals for a new 17 
approach to the management of AF patients, involving a more integrated and holistic 18 
approach11,12. 19 
 20 
In the last two years alone, there have been several new guidelines or guideline 21 
updates that have been published, introducing new recommendations and 22 
significantly revising the previously published ones13–19.  This narrative review aims 23 
to provide a comparison of these contemporary international guidelines or updates, 24 
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with particular attention to the evaluation of thromboembolic and bleeding risks and 1 
management of OAC therapy.  2 
 3 
Overview and General Features of Contemporary Inter national Guidelines 4 
We provide an overview of the new guidelines published in the last two years13–19. 5 
General characteristics of these new guidelines are reported in Table 1.  6 
 7 
In 2016 the Canadian Cardiovascular Society (CCS) published an update13 to their 8 
2010 AF clinical guidelines20, while in 2016 the European Society of Cardiology 9 
(ESC) published their new guidelines14, completely revising the previous main 10 
guideline from 2010 and the 2012 focused update21,22. In 2017, the Asia Pacific 11 
Heart Rhythm Society (APHRS) published their guidelines on stroke prevention in 12 
AF15. Finally, three entirely new guidelines in 2018  from National Heart Foundation 13 
of Australia (NHFA)/Cardiac Society of Australia and New Zealand (CSANZ)16, from 14 
the American College of Chest Physicians (ACCP)17 and Korean Heart Rhythm 15 
Society (KHRS)19 with a second focused updated from the CCS guidelines18 were 16 
published in 2018. 17 
 18 
Five out of seven guidelines performed a systematic search of currently available 19 
evidence based on a structured and established technique used in evidence-based 20 
practice to frame and answer clinical or health related questions, the PICO 21 
(Population, Intervention Comparison, Outcomes) both in its original or modified form 22 
or the clinical questions model13,14,16–18. Conversely, the APHRS and KHRS 23 
guidelines were substantially based on expert consensus review15,19. The ‘Grading of 24 
Recommendations, Assessment, Development and Evaluations’ (GRADE) 25 
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methodology was used to evaluate the quality of scientific evidence in four of the 1 
seven guidelines13,16–18.  Heterogeneity was evident in the grading of the strength of 2 
the recommendations and quality of evidence, with APHRS guidelines not explicitly 3 
grading their recommendations15 and with KHRS ones only grading a limited number 4 
of recommendations19. Concerning conflict of interests, only the ESC, NHFA/CSANZ 5 
and ACCP guidelines14,16,17 provided detailed disclosure of direct, indirect and 6 
potential conflict of interests, with the latter, ACCP, prohibiting voting on those issues 7 
for which an author reported a potential conflict of interest. 8 
 9 
While we found a considerable variability regarding the classification of clinical types 10 
of AF, in particular related to the use of new onset/first detected AF and long-11 
standing persistent AF, there was a substantial agreement across the various 12 
guidelines regarding the definition of non-valvular AF which is generally considered 13 
as the absence of mitral stenosis, even though some guidelines specifically stated 14 
the differential rheumatic or non-rheumatic origin and the degree of disease, and of 15 
mechanical heart valve. Notwithstanding, two guidelines did not assess the 16 
definition15,19. 17 
 18 
Evaluation of Thromboembolic Risk Evaluation and OA C Prescription 19 
When evaluating thromboembolic risk (Table 2), most guidelines recommended the 20 
use of CHA2DS2-VASc score
14–17,19, although the NFHA/CSANZ guidelines used a 21 
modified CHA2DS2-VA score, that no longer consider the role of sex category in 22 
guiding the baseline OAC prescription16. This modification of the CHA2DS2-VASc 23 
score in the NFHA/CSANZ guidelines was justified by differential cut-offs for male 24 
and female AF patients or recommendations to exclude the sex category in the 25 
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evaluation by other guidelines(Table 2)14,15,17,19. The 5 guidelines using CHA2DS2-1 
VASc score, recommend prescribing OAC therapy in all patients with at least 1 non-2 
sex related risk factors14–17,19. Nonetheless, in the ESC, NHFA/CSANZ and KHRS 3 
guidelines, two differential recommendations are provided about patients with only 1 4 
stroke risk factor and for 2 or more stroke risk factors14,16,19. While in the latter 5 
(CHA2DS2-VASc score ≥2) OAC is recommended, with a strong recommendation 6 
based on a high level of evidence, the level of evidence regarding the 7 
recommendation for patients with CHA2DS2-VASc score of 1 is lower, given that 8 
fewer such patients were included in the randomised trials.  9 
 10 
In the 2018 ACCP guidelines, the overall recommendation of prescribing all patients 11 
with at least 1 stroke risk factor is a stroke recommendation based on moderate 12 
quality of evidence17. Of the most recent guidelines, ACCP and KHRS also underline 13 
how, on the basis of some recent evidence, stroke risk assessment needs to be 14 
considered a dynamic process and should be reassessed at the regular follow-up 15 
visits17,19. 16 
 17 
The Canadian guidelines differ from other guidelines since the evaluation of 18 
thromboembolic risk is based on the CHADS-65 algorithm, also known as the CCS 19 
algorithm13,18. This algorithm is a three-step evaluation scheme, that recommends 20 
evaluating the patient’s age first, with all patients aged ≥65 years old recommended 21 
for OAC, followed by assessment of  the presence of stroke risk factors according to 22 
the CHADS2 risk score
23,  where patients with at least 1 risk factor should receive 23 
OAC, and lastly evaluating the presence of coronary artery disease (CAD) or other 24 
arterial vascular disease, recommending the prescription of aspirin in those patients 25 
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aged <65 years with isolated CAD13,18. The Canadian guidelines remain the only one 1 
still recommending the use of aspirin in AF patients aged <65 years with isolated 2 
CAD and no other CHADS2 stroke risk factors. Conversely, all other guidelines firmly 3 
recommend against the use of antiplatelet therapy for thromboembolic risk 4 
treatment14–17,19. 5 
 6 
When OAC is indicated, all guidelines agree about the preferential use of NOACs 7 
over  VKA therapy13–19, with most giving this a strong recommendation,13,14,18,19  All 8 
guidelines concurred with the use of VKAs in patients with valvular AF. Where VKAs 9 
are used, most guidelines (ESC, APHRS, ACCP, KHRS) recommend to maintain a 10 
high quality of OAC control, expressed as time in therapeutic range (TTR) ≥65-11 
70%14,15,17,19. 12 
 13 
Evaluation of Bleeding Risk 14 
After the evaluation of thromboembolic risk, all guidelines point the attention to the 15 
bleeding risk evaluation (Table 3). Most strongly recommend the use of the HAS-16 
BLED risk score to evaluate bleeding risk, with a moderate to a high quality of 17 
evidence13,15,17–19. The ESC guidelines underline how the use of clinical risk scores 18 
could be helpful tools in evaluating bleeding risk, but do not recommend one scheme 19 
over another14. Nonetheless, the ESC guidelines underline how, irrespectively of the 20 
score used, the main aim is to be to identify those patients with modifiable or 21 
potentially modifiable bleeding risk factors14. 22 
 23 
All guidelines agreed that a high bleeding risk should generally not be considered as 24 
a reason to withhold OAC treatment, except those specific situations when the 25 
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risk/benefit ratio excessively favours no antithrombotic13–19. Instead, efforts should 1 
be used to identify all the modifiable bleeding risk factors and address them where 2 
possible, discussing these with the patient, and providing more frequent and regular 3 
checks and follow-up visits13–19. Similarly to thromboembolic risk, ACCP and KHRS 4 
guidelines recommend a reassessment of bleeding risk on a regular basis in light of 5 
its dynamic impact on bleeding risk17,19. 6 
 7 
Utility of Left Atrial Appendage Closure 8 
All the guidelines agreed that left atrial appendage (LAA) closure should not be 9 
routinely used for the management of thromboembolic risk in patients with AF (Table 10 
S1). While the Canadian guidelines suggest, with a low quality of evidence, that LAA 11 
closure should be considered only as part of the ablation procedure, even though 12 
clearly contraindicated in patients at high risk of stroke13,18, other guidelines 13 
recommend that LAA closure should only be considered in those patients with 14 
absolute contra-indications to OAC use14–17,19. Overall, the guidelines judged the 15 
quality of evidence regarding LAA closure to be low. 16 
 17 
Management of OAC and Antiplatelet Therapy 18 
Several epidemiological studies have shown that AF is often associated with acute 19 
coronary syndrome (ACS) and myocardial infarction (MI)24–26. One of the main 20 
concerns in patients presenting with AF and ACS/MI is the management of dual or 21 
triple antithrombotic therapy (OAC plus single or dual antiplatelet therapy) with 22 
respect to balancing atherothrombotic, thromboembolic and bleeding risk.  23 
 24 
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In the antithrombotic decision-making process, a primary distinction has to be drawn 1 
between patients presenting with ACS and those undergoing elective percutaneous 2 
coronary intervention (PCI) with stent. For patients presenting with ACS and 3 
undergoing urgent PCI with stent, almost all the guidelines recommend treatment 4 
with triple antithrombotic, with the duration varying from 1-6 months, with shortening 5 
of triple therapy based on bleeding risk13–18. For example, the recent ACCP 6 
guidelines specifically recommend using triple therapy for 6 months in patients with 7 
low bleeding risk, shortening duration to1 to 3 months in patients with high bleeding 8 
risk, while recommending avoiding it completely in those patients with very high 9 
bleeding risk17. Following the period of triple therapy, duration of dual antithrombotic 10 
therapy should not be continued longer than 12 months after the PCI. In addition, all 11 
guidelines indicate a preference for clopidogrel over aspirin as the choice of 12 
antiplatelet drug. Recommendations regarding patients with ACS and undergoing 13 
urgent PCI (irrespective of stent placement) are generally on the basis of low or 14 
moderate quality of evidence13–18. 15 
 16 
Among patients undergoing elective PCI with stent placement, most of the guidelines 17 
(ESC, APHRS, NHFA/CSANZ, KHRS) recommend a short duration of triple 18 
antithrombotic therapy very short, up to a maximum of 1 month14–16,19. According to 19 
ACCP guidelines in patients with low bleeding risk, the duration of triple therapy is 20 
recommended for 1 month, followed by 12 months of clopidogrel plus OAC; 21 
conversely in patients with high risk of bleeding, while the duration of triple therapy is 22 
kept to 1 month, the guidelines recommend shortening the dual antithrombotic 23 
therapy up to 6 months after the procedure. Finally, in those patients with very high 24 
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bleeding risk use of triple therapy is not recommended, and the duration of dual 1 
antithrombotic therapy should be kept up to 6 months17.  2 
 3 
The Canadian guidelines recommend a bit different approach. In the 2016 update 4 
they did not recommend at all use of triple therapy for elective PCI, suggesting only 5 
dual antithrombotic therapy with clopidogrel. In the 2018 version, they changed the 6 
recommendations by introducing the use of triple antithrombotic therapy in elective 7 
PCI in consideration of the high risk of thrombotic coronary events associated with 8 
some clinical variables (i.e. diabetes mellitus, smoking, chronic kidney disease, 9 
previous coronary events, etc.) and of type of stent13,18. Those patients with high risk 10 
features are recommended to be treated for up to 6 months with triple antithrombotic 11 
therapy, followed by dual therapy for up to 12 months post stent. However, in 12 
patients without high risk features, triple therapy is not recommended18. It is 13 
important to underline that all the recommendations regarding the use of triple 14 
therapy in AF patients receiving elective PCI are weak and based on moderate to 15 
low quality of evidence. 16 
 17 
Regarding OAC prescription, the CCS, APHRS, KHRS guidelines recommend 18 
NOACs over VKAs in ACS patients, although there is less robust  evidence13,15,18,19. 19 
While the NHFA/CSANZ guidelines do not provide any particular recommendation in 20 
this regard16. The ESC guidelines recommend the use of the lowest approved 21 
dosage of NOACs when co-administered with antiplatelet drugs14, while the ACCP 22 
guidelines recommend NOACs as equal to VKAs, but with a weaker 23 
recommendation based on a lower quality of evidence17. 24 
 25 
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Management of Oral Anticoagulant in Cardioversion a nd Ablation Procedures 1 
With regard to ablation procedures, all guidelines agree on three main pillars: i) 2 
uninterrupted OAC is recommended for patients undergoing ablation procedure; ii) 3 
after procedure, OAC therapy is recommended as compulsory for at least 8 weeks in 4 
all the patients; iii) long-term OAC prescription beyond the first 8 weeks, should be 5 
based on risk profile and proposed only to patients with high risk of stroke14,15,17–19.  6 
 7 
Regarding the type of OAC to be prescribed for pre- and peri-procedural 8 
uninterrupted treatment, the ESC, APHRS and CCS 2018 guidelines all recommend 9 
NOACs and VKAs as equal alternatives14,15,18. As a notable exception, the recent 10 
ACCP guidelines only recommend dabigatran or rivaroxaban among the NOACs17. 11 
 12 
With respect to OAC in patients undergoing a cardioversion procedure, all the 13 
guidelines agreed on some basic principles: i) in patients with at least 48 hours of 14 
proved AF, anticoagulation should be provided for at least 3 weeks to exclude the 15 
presence of any left atrial thrombus; ii) as an alternative to OAC, use of a trans-16 
esophageal echocardiogram to exclude the presence of any left atrial thrombus; iii) 17 
OAC should be continued for at least 4 weeks after procedure, irrespective of the 18 
success of cardioversion procedure13–19. Most of the guidelines agree that long-term 19 
OAC, irrespective of the success of cardioversion procedure, should be considered 20 
on the basis of stroke risk factors14–19. Several guidelines also explicitly 21 
recommended to provide 3 to 4 weeks OAC treatment if a thrombus is identified on 22 
the trans-esophageal echocardiogram14,15,17,19. ACCP 2018 and CCS 2018 23 
guidelines provided recommendations regarding specific situations. ACCP guidelines 24 
provide an indication about not commencing OAC for patients with <48 hours AF and 25 
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hemodynamic instability, rather initiate parenteral anticoagulation as soon as it is 1 
possible17. In the CCS 2018 guidelines, is indicated that in patients with very short 2 
(<12 hours) or short (12-48 hours) AF duration, OAC can be avoided if there is no 3 
substantial risk of stroke18. 4 
 5 
Management of OAC in Specific Populations 6 
One of the most debated issues in the management of OAC therapy is the 7 
prescription in elderly (very elderly) and frail patients (Table S2). Among the 8 
guidelines examined, the CCS (having discussed the issue in the previous 2010 and 9 
2012 versions, but they do not make any recommendations in 2016 and 2018), and 10 
APHRS guidelines did not consider this issue13,15,18.  11 
 12 
The ESC guidelines state that the available evidence supports the use of OAC in 13 
elderly and frail subjects, due to the high benefit-risk ratio14. The NHFA/CSANZ 14 
guidelines highlight the beneficial effect of OAC in elderly patients observed in 15 
observational registries, with a preference for the use of NOACs, due to the high 16 
prevalence of polypharmacy, although caution is recommended with dose-17 
adjustment related to renal function16. The ACCP guidelines recommend a specific 18 
individual risk assessment prior to OAC prescription while reaffirming that the benefit 19 
of OAC prescription generally outweigh the risk of harm from serious bleeding, whilst 20 
highlighting a contraindication to OAC prescription is posed for patients with 21 
dementia and no caregiver (to administer OAC)17. Similar recommendations are 22 
included in the KHRS guidelines19. Guidelines including specific recommendations 23 
about elderly patients did not rate these recommendations. 24 
 25 
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Another important population is are patients with chronic kidney disease. Impaired 1 
renal function is an independent risk factor for stroke, major bleeding and major 2 
adverse outcomes in patients with AF27, thus these patients need careful 3 
management in order to maximize stroke prevention and reduce bleeding risk, and 4 
the guidelines differ in their recommendations for managing such patients (Table S2) 5 
and the lower limit for which OAC use is no longer recommended. Both Canadian 6 
guidelines suggest that OAC should not be routinely prescribed for patients with 7 
glomerular filtration rate (GFR) <15 mL/min, but that use of OAC may be appropriate 8 
in some patients in whom there is a stronger preference in avoiding stroke despite 9 
the uncertain benefit and the associated bleeding risk13,18. Lack of data, with limited 10 
evidence about efficacy and safety of OAC in patients with GFR <30 mL/min and 11 
<15 mL/min are claimed by APHRS15, NHFA/CSANZ16 and ESC guidelines14. 12 
Although the APHRS, ACCP and KHRS guidelines recognise the limited evidence, 13 
they suggest that use of VKAs with well-managed quality of anticoagulation therapy 14 
could be considered15,17,19. 15 
 16 
In patients with moderate to severe CKD (GFR 15-30 mL/min), treatment strategies 17 
differ across guidelines. Both Canadian guidelines recommend OAC prescription on 18 
the basis of stroke risk, with warfarin the preferred agent13,18, while the APHRS, 19 
ACCP and KHRS guidelines suggest the use of OAC with caution, with the 20 
recommendation to reduce NOACs dosages.15,17,19 The ESC guidelines also 21 
recommend reducing the NOAC dosage, although the reduction is suggested for 22 
patients with GRF 25-50 mL/min. The adjustment of NOACs dosage is also 23 
suggested by the other guidelines for patients with GFR >30 and up to 50 or 60 24 
mL/min, according to guidelines13,15,17–19. It is relevant to note that the majority of the 25 
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recommendations are weak and based on a low quality of evidence, underlining the 1 
need for more solid evidence. 2 
 3 
One emergent issue is that related to the treatment of patients with cardiac 4 
implantable electronic devices, without clinical AF, that are found to have atrial high 5 
rate episodes (AHREs). While some guidelines did not consider this issue15,19, others 6 
suggest that OAC treatment should be considered in those with prolonged AHREs 7 
(>24 hours) and a high risk of stroke (CHA2DS2-VASc ≥2),
13,16–18 while further data 8 
are needed to support the use of OAC in patients with AHREs of shorter duration. 9 
However, the ESC guidelines do not advocate OAC treatment for patients with 10 
AHREs14. 11 
 12 
Use of an Integrated Management in Patients with At rial Fibrillation 13 
Given the increased risk for adverse outcomes other than stroke, such as myocardial 14 
infarction, cardiovascular death and all-cause death,9,10,24,25 in AF patients, there is a 15 
need for a more integrated and holistic management approach for AF patients, in 16 
order to reduce overall cardiovascular risk11,12. Most guidelines advocate the need 17 
for an integrated approach (Table S3), for example, in the 2016 ESC guidelines, in 18 
order to improve adherence to treatment, quality of life and long-term outcomes14,16–19 
19. However, the operationalisation and implementation of integrated care needs to 20 
be simple and practical. To address the latter, both the ACCP and KHRS guidelines 21 
have suggested that use of the ‘Atrial Fibrillation Better Care’ (ABC)28 approach as a 22 
practical tool to streamline the integrated management of AF patients17,19. 23 
 24 
  25 
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SUMMARY AND DISCUSSION 1 
In this narrative review, we have discussed the main recommendations regarding 2 
OAC management for AF patients from contemporary international guidelines. Most 3 
guidelines were compiled with a systematic and well-established approach and rated 4 
according to a rigorous evaluation system. There was general agreement in the 5 
definition of valvular and non-valvular AF, although some heterogeneity was evident 6 
in the temporal classification of AF. Despite not being considered in the OAC 7 
decision-making process, the type of AF can influence the risk of major adverse 8 
outcomes29. Further, the classification of clinical AF influences rate/rhythm 9 
management and lack of concordance between the guidelines can be misleading in 10 
the evaluation of patients and differing management strategies between physicians. 11 
 12 
Evaluation of thromboembolic risk at baseline is very similar across all the guidelines 13 
with most adopting the CHA2DS2-VASc score, with the notable exception of 14 
Canadian guidelines. The almost universal adoption of CHA2DS2-VASc score 15 
reflects the strength of the current data supporting its’ use a clinical risk score that 16 
provides a balance between evidence, practicality and precision30. A recent 17 
comparative effectiveness review about the ability of the scores to predict 18 
thromboembolic and bleeding events reported that CHADS2, CHA2DS2-VASc and 19 
the recent ABC-Stroke31 scores were best and had a similar predictive capacity for 20 
stroke occurrence32. Nonetheless, CHA2DS2-VASc differs from other scores for its 21 
capacity to effectively identify those patients with very low risk and does not require 22 
expensive and time-consuming laboratory tests to be undertaken compared to the 23 
ABC-Stroke score30. Furthermore, recently a systematic review and meta-regression 24 
demonstrated that CHA2DS2-VASc score represents the score with the highest 25 
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probability to perform best in predicting the occurrence of all-cause death in AF 1 
patients33.  2 
 3 
The role of the female sex as an independent risk factor, in relation to stroke risk is 4 
addressed by all the seven guidelines examined (Table 2)13–19. The increased stroke 5 
risk in female AF patients has been long discussed34,35. A comprehensive meta-6 
analysis including almost 1 million AF patients demonstrated that female patients 7 
with AF were at increased risk of stroke, with a 24% of relative risk increase36. 8 
However, a significant relationship was found between increasing age and a 9 
progressively higher risk of stroke in female AF patients36. Compelling data from the 10 
Danish registries demonstrated that while there were no profound differences 11 
between ‘low risk’ male and female AF patients with no additional stroke risk factors, 12 
a sex difference in stroke risk increased with the increasing number of risk factors, 13 
suggesting that female sex was “risk modifier” rather  than a risk factor per se37.  14 
Ignoring the female sex criterion would underestimate stroke risk in female patients 15 
with ≥1 additional stroke risk factor(s), an important consideration when discussing 16 
risks with AF patients.    17 
 18 
The second pivotal step on which all the guidelines agree is the evaluation of 19 
baseline bleeding risk. While five out of 7 of the guidelines examined adopted HAS-20 
BLED as the clinical risk score to evaluate bleeding risk13,15,17–19, the ESC and 21 
NHFA/CSANZ guidelines recognize the utility of the clinical scores to evaluate 22 
bleeding risk, but do not recommend the use of any particular score14,16. Conversely, 23 
these guidelines adopt an approach based on the identification of modifiable and 24 
potentially modifiable bleeding risk factors,14,16 despite evidence demonstrating the 25 
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superiority of HAS-BLED to ORBIT, ATRIA Bleeding, HEMORR2HAGES scores
38,39 1 
and to the most recent ABC-Bleeding and GARFIELD-AF Bleeding scores.40,41  2 
Furthermore, when compared to an approach based exclusively on modifiable 3 
bleeding risk factors as promoted by the ESC guidelines, using the HAS-BLED score 4 
was a superior strategy for bleeding risk assessment 42,43. 5 
 6 
Regarding the prescription of OAC, the Canadian guidelines still recommend 7 
prescribing antiplatelet drugs in patients aged <65 years with isolated CAD and no 8 
other stroke risk factors13,18, but all other guidelines support the prescription of OAC 9 
in patients with at least one stroke risk factor not related to gender. All the 10 
recommendations regarding OAC prescription are strong recommendations and 11 
hence supported by solid evidence. Similarly, as largely supported by Phase III 12 
randomized clinical trials2 and observational studies44–46, all the guidelines 13 
recommend the use of NOACs in preference to VKAs. Notwithstanding that globally 14 
VKAs are still widely used as OAC, the use of the SAMe-TT2R2 score is mentioned 15 
in some guidelines related to where VKAs are used to help assess the likelihood of 16 
patients to achieve an optimal anticoagulation control when prescribed with VKAs, 17 
that could guide more intense INR monitoring or the alternative prescription of VKAs 18 
and NOACs47. 19 
 20 
On the basis of the guideline recommendations and evidence presented, and given 21 
that the default should be to offer stroke prevention unless the patient is ‘low risk’, 22 
the so-called ‘Birmingham 3-Step’ management strategy has been advocated [Figure 23 
2]1. In the first step, AF patients who are low risk are identified through CHA2DS2-24 
VASc score, and no antithrombotic therapy is recommended. In the second step, 25 
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OAC therapy is considered in all AF patients with at least 1 additional non-sex stroke 1 
risk factor(s) and risk of bleeding is assessed, to identify those patients at high risk of 2 
bleeding (HAS-BLED ≥3), to address modifiable bleeding risk factors and plan more 3 
frequent follow-up checks. In the third step, treatment with OAC should be started 4 
with NOACs as the preferred option – and if a VKA is considered, the SAMe-TT2R2 5 
score can help to identify those patients that would more likely obtain a low TTR 6 
(SAMe-TT2R2 >2) who can be identified for more regular INR monitoring, 7 
education/counselling or to reconsider being prescribed a NOAC. 8 
 9 
Regarding the concomitant use of OAC and antiplatelet drugs, the guidelines 10 
examined agree on similar basis. It is recognized that the use of triple antithrombotic 11 
therapy in AF with ACS should be based on the balance between 12 
atherothrombotic/thromboembolic risk and bleeding risk and that such strategy 13 
should be kept as short as possible. 14 
 15 
Use of triple antithrombotic therapy has been traditionally associated to an increased 16 
risk of bleeding, with several studies reporting an increased rate of major bleeding 17 
events with no relative benefit in terms of thromboembolic and atherosclerotic 18 
events)48,49. For example, the WOEST trial reported that a strategy of clopidogrel 19 
plus OAC compared to triple antithrombotic therapy was associated with a lower risk 20 
of major bleeding with no difference in terms of efficacy48.  Nevertheless, if good 21 
quality anticoagulation control is attained, the risk of major bleeding in such patients 22 
undergoing PCI and stent seems to be significantly reduced49. The 2018 joint 23 
European consensus document underlined the need to shorten triple antithrombotic 24 
therapy in AF patients as much as possible, related to clinical presentation, bleeding 25 
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risk, etc50. In this situation, a strategy based on NOACs was associated with a 1 
reduced risk of major bleeding events51,52. However, a network meta-analysis 2 
concluded that the best treatment strategy for these high-risk patients still appears to 3 
be the use of a VKA and single antiplatelet drugs when considering both efficacy and 4 
safety, even though the use of low-dose rivaroxaban appears as a valid alternative53.  5 
Nevertheless, this network meta-analysis did not include data from the RE-DUAL 6 
PCI trial52. Future results from other ongoing trials (AUGUSTUS ClinicalTrials.Gov: 7 
NCT02415400; ENTRUST-AF-PCI ClinicalTrials.Gov: NCT02866175) will provide 8 
further evidence. 9 
 10 
In the clinical scenarios of catheter ablation and cardioversion procedures, the 11 
guidelines reviewed shared similar approaches regarding the use of OAC and 12 
NOACs. Several studies have examined the use of uninterrupted NOACs in the 13 
catheter ablation setting and all data support better safety profile compared to VKAs, 14 
with no differences in terms of efficacy54,55.  In the cardioversion setting NOACs were 15 
similar to VKAs in terms of both efficacy and safety56. 16 
 17 
With regard to specific populations (patients with chronic kidney disease, the elderly 18 
and frail, patients with AHREs), the guidelines highlight the absence of specific 19 
controlled studies exploring the efficacy and safety of OAC and NOACs in these 20 
populations. Even though observational data are available and subgroups analysis 21 
provided some evidence to draft some recommendations, this evidence was not 22 
considered solid enough to provide strong recommendations. Future studies are still 23 
needed in patients with chronic kidney disease and those elderly and frail to better 24 
substantiate current clinical practice. Regarding patients with AHREs, some studies 25 
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are currently in progress and will elucidate the risk-benefit ratio of treating these 1 
patients with OAC57,58. 2 
 3 
In some of the contemporary guidelines, the need for integrated management for AF 4 
patients is highlighted. On the basis of the evidence that AF patients are burdened 5 
with an increased risk of major adverse outcomes beyond their mere 6 
thromboembolic risks9,10,24,25, an approach that would account for the multiple issues 7 
related to the clinical management of these patients is needed11,12. The 2016 ESC 8 
guidelines refer to the ‘domains of AF management’ and the need for a 9 
multidisciplinary approach to AF management (with so-called ‘Heart Team’) but the 10 
operationalisation of such an approach requires simple and practical approaches for 11 
the AF patient management pathway. 12 
 13 
Indeed, the use of an integrated management approach to AF is associated with a 14 
reduced risk of all-cause death, cardiovascular death and rehospitalization59,60 61.  15 
Compliance with the ABC pathway is also associated with reduced healthcare 16 
costs62. As recently highlighted by some guidelines17,19, the ABC pathway has been 17 
proposed to streamline an integrated and holistic management approach for patients 18 
with AF [Figure 3]28.   19 
 20 
Significant differences are evicent between the various guidelines examined for 21 
some key issues. For example, the CCS guidelines in not indicating the use of OAC 22 
in patients <65 years with isolated CAD13,18 represent one example. This notable 23 
exception have been firstly reported in the CCS guidelines in the 2012 update63 and 24 
it stands on the assumption that CAD implies a low risk of stroke in AF patients 25 
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(<1.5% per year)63.  Several data exist show that in AF patients, the presence of 1 
vascular disease and CAD are associated to a significant independent increase in 2 
stroke risk64–66.   3 
 4 
Even more differences are related to those issues for which a lower quality of 5 
evidence and strength of recommendations is available. These reflect the lack of 6 
high-quality data obtained from randomized controlled trials and underline the need 7 
for future well-designed and adequately powered studies. 8 
 9 
The use of an approach based on expert consensus review of the published 10 
evidence for the APHRS and KHRS guidelines15,19 could impact on the daily clinical 11 
decision-making process, but when a high quality of evidence is available these 12 
guidelines are still able to provide solid recommendations. For all the other aspects 13 
for which there is a significant degree of uncertainty, there may be a less objective 14 
evaluation of the limited scientific evidence available. In any case, many guidelines 15 
that use systematic reviews still include many recommendations with Level of 16 
Evidence C, which represents expert consensus anyway.    17 
 18 
CONCLUSION 19 
In this narrative review of contemporary guidelines, there is general agreement on 20 
the baseline evaluation of thromboembolic and bleeding risk, as well as a preference 21 
for the use of NOACs. More data are still needed to better substantiate 22 
recommendations for specific AF subpopulations. The need for an integrated 23 
approach and holistic management is highlighted in the more recently published 24 
guidelines. 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 23
 1 
FUNDING 2 
No funding was used to prepare this paper. 3 
 4 
DISCLOSURE OF INTERESTS 5 
MP reports consulting activity for Boehringer Ingelheim; DAL reports investigator-6 
initiated educational grants from Bristol-Myers Squibb and Boehringer Ingelheim; 7 
speaker activity for Boehringer Ingelheim, Bayer and Bristol-Myers Squibb /Pfizer; 8 
consultant activity for Bristol-Myers Squibb, Bayer, Boehringer Ingelheim and 9 
Daiichi-Sankyo; She is a member of the ACCP 2018 writing committee; GB has 10 
received small speaker’s fee from Medtronic, Boston, Boehringer and Bayer, outside 11 
the submitted work; He is a member of the ACCP 2018 writing committee; GYHL has 12 
served as consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer 13 
Ingelheim, Novartis, Verseon and Daiichi-Sankyo; and speaker for Bayer, 14 
BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. He is member 15 
and chair of the ACCP 2018 writing committee. No fees are received personally. 16 
 17 
                       18 
 19 
 20 
 21 
  22 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 24
REFERENCES 1 
1.  Lip G, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial 2 
fibrillation: Past, present and future. Comparing the guidelines and practical 3 
decision-making. Thromb. Haemost. 2017;117(7):1230-1239. 4 
doi:10.1160/TH16-11-0876. 5 
2.  Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and 6 
safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: 7 
a meta-analysis of randomised trials. Lancet 2013. doi:10.1016/S0140-8 
6736(13)62343-0. 9 
3.  Gadsbøll K, Staerk L, Loldrup Fosbøl E, et al. Increased use of oral 10 
anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 11 
2015 in Denmark. Eur. Heart J. 2017;38(12):899-906. 12 
doi:10.1093/eurheartj/ehw658. 13 
4.  Marzec LN, Wang J, Shah ND, et al. Influence of Direct Oral Anticoagulants on 14 
Rates of Oral Anticoagulation for Atrial Fibrillation. J. Am. Coll. Cardiol. 15 
2017;69(20):2475-2484. doi:10.1016/j.jacc.2017.03.540. 16 
5.  Camm AJ, Accetta G, Ambrosio G, et al. Evolving antithrombotic treatment 17 
patterns for patients with newly diagnosed atrial fibrillation. Heart 18 
2017;103(4):307-314. doi:10.1136/heartjnl-2016-309832. 19 
6.  Boriani G, Proietti M, Laroche C, et al. Contemporary stroke prevention 20 
strategies in 11 096 European patients with atrial fibrillation: a report from the 21 
EURObservational Research Programme on Atrial Fibrillation (EORP-AF) 22 
Long-Term General Registry. Europace 2017;(November):1-11. 23 
doi:10.1093/europace/eux301. 24 
7.  Marijon E, Le Heuzey J-Y, Connolly S, et al. Causes of death and influencing 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 25
factors in patients with atrial fibrillation: a competing-risk analysis from the 1 
randomized evaluation of long-term anticoagulant therapy study. Circulation 2 
2013;128(20):2192-2201. doi:10.1161/CIRCULATIONAHA.112.000491. 3 
8.  Fauchier L, Villejoubert O, Clementy N, et al. Causes of Death and Influencing 4 
Factors in Patients with Atrial Fibrillation. Am. J. Med. 2016. 5 
doi:10.1016/j.amjmed.2016.06.045. 6 
9.  Proietti M, Laroche C, Opolski G, et al. “Real-world” atrial fibrillation 7 
management in Europe: observations from the 2-year follow-up of the 8 
EURObservational Research Programme-Atrial Fibrillation General Registry 9 
Pilot Phase. Europace 2017;19(5):722-733. doi:10.1093/europace/euw112. 10 
10.  Proietti M, Laroche C, Nieuwlaat R, et al. Increased burden of comorbidities 11 
and risk of cardiovascular death in atrial fibrillation patients in Europe over ten 12 
years: A comparison between EORP-AF pilot and EHS-AF registries. Eur. J. 13 
Intern. Med. 2018. doi:10.1016/j.ejim.2018.05.016. 14 
11.  Kotecha D, Breithardt G, Camm AJ, et al. Integrating new approaches to atrial 15 
fibrillation management: The 6th AFNET/EHRA Consensus Conference. 16 
Europace 2018;20(3):395-407. doi:10.1093/europace/eux318. 17 
12.  Kirchhof P. The future of atrial fibrillation management: integrated care and 18 
stratified therapy. Lancet (London, England) 2017;390(10105):1873-1887. 19 
doi:10.1016/S0140-6736(17)31072-3. 20 
13.  Macle L, Cairns J, Leblanc K, et al. 2016 Focused Update of the Canadian 21 
Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. 22 
Can. J. Cardiol. 2016. doi:10.1016/j.cjca.2016.07.591. 23 
14.  Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the 24 
management of atrial fibrillation developed in collaboration with EACTS. Eur. 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 26
Heart J. 2016;37(38):2893-2962. doi:10.1093/eurheartj/ehw210. 1 
15.  Chiang C-E, Okumura K, Zhang S, et al. 2017 consensus of the Asia Pacific 2 
Heart Rhythm Society on stroke prevention in atrial fibrillation. J. Arrhythmia 3 
2017;33(4):345-367. doi:10.1016/j.joa.2017.05.004. 4 
16.  NHFA CSANZ Atrial Fibrillation Guideline Working Group D, Brieger D, 5 
Amerena J, et al. National Heart Foundation of Australia and the Cardiac 6 
Society of Australia and New Zealand: Australian Clinical Guidelines for the 7 
Diagnosis and Management of Atrial Fibrillation 2018. Heart. Lung Circ. 8 
2018;27(10):1209-1266. doi:10.1016/j.hlc.2018.06.1043. 9 
17.  Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic Therapy for Atrial 10 
Fibrillation: CHEST Guideline and Expert Panel Report. Chest 11 
2018;154(5):1121-1201. doi:10.1016/j.chest.2018.07.040. 12 
18.  Andrade JG, Verma A, Mitchell LB, et al. 2018 Focused Update of the 13 
Canadian Cardiovascular Society Guidelines for the Management of Atrial 14 
Fibrillation. Can. J. Cardiol. 2018;34(11):1371-1392. 15 
doi:10.1016/j.cjca.2018.08.026. 16 
19.  Joung B, Lee JM, Lee KH, et al. 2018 Korean Guideline of Atrial Fibrillation 17 
Management. Korean Circ. J. 2018;48(12):1033. doi:10.4070/kcj.2018.0339. 18 
20.  Gillis AM, Skanes AC, Committee CCSAFG. Canadian Cardiovascular Society 19 
atrial fibrillation guidelines 2010: implementing GRADE and achieving 20 
consensus. Can J Cardiol 2011;27(1):27-30. doi:10.1016/j.cjca.2010.11.003. 21 
21.  Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial 22 
fibrillation. Eur. Heart J. 2010;31(19):2369-2429. 23 
doi:10.1093/eurheartj/ehq278. 24 
22.  Camm A, Lip G, De Caterina R, et al. 2012 focused update of the ESC 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 27
Guidelines for the management of atrial fibrillation: an update of the 2010 ESC 1 
Guidelines for the management of atrial fibrillation. Developed with the special 2 
contribution of the European Heart Rhythm Association. Eur Hear. J 3 
2012;33:2719-2747. 4 
23.  Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. 5 
Validation of clinical classification schemes for predicting stroke: results from 6 
the National Registry of Atrial Fibrillation. JAMA 2001;285(22):2864-70. 7 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/11401607. Accessed 8 
November 3, 2014. 9 
24.  Soliman EZ, Safford MM, Muntner P, et al. Atrial fibrillation and the risk of 10 
myocardial infarction. JAMA Intern. Med. 2014;174(1):107-14. 11 
doi:10.1001/jamainternmed.2013.11912. 12 
25.  Soliman EZ, Lopez F, O’Neal WT, et al. Atrial Fibrillation and Risk of ST-13 
Segment-Elevation Versus Non-ST-Segment-Elevation Myocardial Infarction: 14 
The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 15 
2015;131(21):1843-50. doi:10.1161/CIRCULATIONAHA.114.014145. 16 
26.  Violi F, Davì G, Proietti M, et al. Ankle-Brachial Index and cardiovascular 17 
events in atrial fibrillation: The ARAPACIS study. Thromb. Haemost. 18 
2016;115(4). doi:10.1160/TH15-07-0612. 19 
27.  Lau YC, Proietti M, Guiducci E, Blann AD, Lip GYH. Atrial Fibrillation and 20 
Thromboembolism in Patients With Chronic Kidney Disease. J. Am. Coll. 21 
Cardiol. 2016;68(13). doi:10.1016/j.jacc.2016.06.057. 22 
28.  Lip GYH. The ABC pathway: an integrated approach to improve AF 23 
management. Nat. Rev. Cardiol. 2017;14(11):627-628. 24 
doi:10.1038/nrcardio.2017.153. 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 28
29.  Ganesan AN, Chew DP, Hartshorne T, et al. The impact of atrial fibrillation 1 
type on the risk of thromboembolism, mortality, and bleeding: a systematic 2 
review and meta-analysis. Eur. Heart J. 2016;37(20):1591-1602. 3 
doi:10.1093/eurheartj/ehw007. 4 
30.  Proietti M, Mujovic N, Potpara TS. Optimizing Stroke and Bleeding Risk 5 
Assessment in Patients with Atrial Fibrillation: A Balance of Evidence, 6 
Practicality and Precision. Thromb. Haemost. 2018;118(12):2014-2017. 7 
doi:10.1055/s-0038-1676074. 8 
31.  Oldgren J, Hijazi Z, Lindbäck J, et al. Performance and Validation of a Novel 9 
Biomarker-Based Stroke Risk Score for Atrial FibrillationClinical Perspective. 10 
Circulation 2016;134(22):1697-1707. 11 
doi:10.1161/CIRCULATIONAHA.116.022802. 12 
32.  Borre ED, Goode A, Raitz G, et al. Predicting Thromboembolic and Bleeding 13 
Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic 14 
Review. Thromb. Haemost. 2018;118(12):2171-2187. doi:10.1055/s-0038-15 
1675400. 16 
33.  Proietti M, Farcomeni A, Romiti GF, et al. Association between clinical risk 17 
scores and mortality in atrial fibrillation: Systematic review and network meta-18 
regression of 669,000 patients. Eur. J. Prev. Cardiol. 2018:204748731881766. 19 
doi:10.1177/2047487318817662. 20 
34.  Lane DA, Lip GYH. Female gender is a risk factor for stroke and 21 
thromboembolism in atrial fibrillation patients. Thromb. Haemost. 22 
2009;101(5):802-5. 23 
35.  Poli D, Antonucci E. Epidemiology, diagnosis, and management of atrial 24 
fibrillation in women. Int. J. Womens. Health 2015;7:605-14. 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 29
doi:10.2147/IJWH.S45925. 1 
36.  Marzona I, Proietti M, Farcomeni A, et al. Sex differences in stroke and major 2 
adverse clinical events in patients with atrial fibrillation: A systematic review 3 
and meta-analysis of 993,600 patients. Int. J. Cardiol. 2018. 4 
doi:10.1016/j.ijcard.2018.07.044. 5 
37.  Nielsen PB, Skjøth F, Overvad TF, Larsen TB, Lip GYH. Female Sex Is a Risk 6 
Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We 7 
Use a CHA2DS2-VA Score Rather Than CHA2DS2-VASc? Circulation 8 
2018;137(8):832-840. doi:10.1161/CIRCULATIONAHA.117.029081. 9 
38.  Senoo K, Proietti M, Lane DA, Lip GYH. Evaluation of the HAS-BLED, ATRIA 10 
and ORBIT bleeding risk scores in atrial fibrillation patients on warfarin. Am. J. 11 
Med. 2015. doi:10.1016/j.amjmed.2015.10.001. 12 
39.  Proietti M, Senoo K, Lane DA, Lip GYH. Major Bleeding in Patients with Non-13 
Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on 14 
Contemporary Bleeding Risk Scores. Sci. Rep. 2016;6:24376. 15 
doi:10.1038/srep24376. 16 
40.  Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V, et al. Long-term bleeding 17 
risk prediction in “real world” patients with atrial fibrillation: Comparison of the 18 
HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation 19 
Project. Thromb Haemost 2017;117(10):1848-1858. doi:10.1160/th17-07-20 
0478. 21 
41.  Proietti M, Rivera‐Caravaca JM, Esteve‐Pastor MA, Romiti GF, Marin F, Lip 22 
GYH. Predicting Bleeding Events in Anticoagulated Patients With Atrial 23 
Fibrillation: A Comparison Between the HAS‐BLED and GARFIELD‐AF 24 
Bleeding Scores. J. Am. Heart Assoc. 2018;7(18). 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 30
doi:10.1161/JAHA.118.009766. 1 
42.  Chao T-F, Lip GYH, Lin Y-J, et al. Incident Risk Factors and Major Bleeding in 2 
Patients with Atrial Fibrillation Treated with Oral Anticoagulants: A Comparison 3 
of Baseline, Follow-up and Delta HAS-BLED Scores with an Approach 4 
Focused on Modifiable Bleeding Risk Factors. Thromb. Haemost. 5 
2018;118(4):768-777. doi:10.1055/s-0038-1636534. 6 
43.  Esteve-Pastor MA, Rivera-Caravaca JM, Shantsila A, Roldán V, Lip GYH, 7 
Marín F. Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a 8 
Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against 9 
the HAS-BLED Score. The AMADEUS Trial. Thromb. Haemost. 10 
2017;117(12):2261-2266. doi:10.1160/TH17-10-0710. 11 
44.  Carmo J, Moscoso Costa F, Ferreira J, Mendes M. Dabigatran in real-world 12 
atrial fibrillation. Meta-analysis of observational comparison studies with 13 
vitamin K antagonists. Thromb. Haemost. 2016;116(4):754-763. 14 
doi:10.1160/TH16-03-0203. 15 
45.  Bai Y, Deng H, Shantsila A, Lip GYH. Rivaroxaban Versus Dabigatran or 16 
Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation. 17 
Stroke 2017;48(4):970-976. doi:10.1161/STROKEAHA.116.016275. 18 
46.  Proietti M, Romanazzi I, Romiti GF, Farcomeni A, Lip GYH. Real-world use of 19 
apixaban for stroke prevention in atrial fibrillation: A systematic review and 20 
meta-analysis. Stroke 2018;49(1):98-106. 21 
doi:10.1161/STROKEAHA.117.018395. 22 
47.  Zulkifly H, Lip GYH, Lane DA. Use of the SAMe-TT 2 R 2 score to predict 23 
anticoagulation control in atrial fibrillation and venous thromboembolism 24 
patients receiving vitamin K antagonists: A review. Hear. Rhythm 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 31
2018;15(4):615-623. doi:10.1016/j.hrthm.2017.11.026. 1 
48.  Dewilde WJM, Oirbans T, Verheugt FWA, et al. Use of clopidogrel with or 2 
without aspirin in patients taking oral anticoagulant therapy and undergoing 3 
percutaneous coronary intervention: an open-label, randomised, controlled 4 
trial. Lancet 2013;381(9872):1107-1115. doi:10.1016/S0140-6736(12)62177-1. 5 
49.  Proietti M, Airaksinen KEJJ, Rubboli A, et al. Time in therapeutic range and 6 
major adverse outcomes in atrial fibrillation patients undergoing percutaneous 7 
coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery 8 
Stenting (AFCAS) registry. Am. Heart J. 2017;190:86-93. 9 
doi:10.1016/j.ahj.2017.05.016. 10 
50.  Lip GYH, Collet J-P, Haude M, et al. 2018 Joint European consensus 11 
document on the management of antithrombotic therapy in atrial fibrillation 12 
patients presenting with acute coronary syndrome and/or undergoing 13 
percutaneous cardiovascular interventions: a joint consensus document of the 14 
Europ. Europace 2018. doi:10.1093/europace/euy174. 15 
51.  Gibson CM, Mehran R, Bode C, et al. Prevention of Bleeding in Patients with 16 
Atrial Fibrillation Undergoing PCI. N. Engl. J. Med. 2016;375(25):2423-2434. 17 
doi:10.1056/NEJMoa1611594. 18 
52.  Cannon CP, Bhatt DL, Oldgren J, et al. Dual Antithrombotic Therapy with 19 
Dabigatran after PCI in Atrial Fibrillation. N. Engl. J. Med. 20 
2017:NEJMoa1708454. doi:10.1056/NEJMoa1708454. 21 
53.  Gong X, Tang S, Li J, Zhang X, Tian X, Ma S. Antithrombotic therapy 22 
strategies for atrial fibrillation patients undergoing percutaneous coronary 23 
intervention: A systematic review and network meta-analysis. Pizzi C, ed. 24 
PLoS One 2017;12(10):e0186449. doi:10.1371/journal.pone.0186449. 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 32
54.  Ge Z, Faggioni M, Baber U, et al. Safety and efficacy of nonvitamin K 1 
antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A 2 
systematic review and meta-analysis. Cardiovasc. Ther. 2018;36(5):e12457. 3 
doi:10.1111/1755-5922.12457. 4 
55.  Zhao Y, Lu Y, Qin Y. A meta-analysis of randomized controlled trials of 5 
uninterrupted periprocedural anticoagulation strategy in patients undergoing 6 
atrial fibrillation catheter ablation. Int. J. Cardiol. 2018;270:167-171. 7 
doi:10.1016/j.ijcard.2018.06.024. 8 
56.  Brunetti ND, Tarantino N, De Gennaro L, Correale M, Santoro F, Di Biase M. 9 
Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion 10 
of atrial fibrillation: an updated meta-analysis. J. Thromb. Thrombolysis 11 
2018;45(4):550-556. doi:10.1007/s11239-018-1622-5. 12 
57.  Lopes RD, Alings M, Connolly SJ, et al. Rationale and design of the Apixaban 13 
for the Reduction of Thrombo-Embolism in Patients With Device-Detected 14 
Sub-Clinical Atrial Fibrillation (ARTESiA) trial. Am. Heart J. 2017;189:137-145. 15 
doi:10.1016/j.ahj.2017.04.008. 16 
58.  Kirchhof P, Blank BF, Calvert M, et al. Probing oral anticoagulation in patients 17 
with atrial high rate episodes: Rationale and design of the Non-vitamin K 18 
antagonist Oral anticoagulants in patients with Atrial High rate episodes 19 
(NOAH-AFNET 6) trial. Am. Heart J. 2017;190:12-18. 20 
doi:10.1016/j.ahj.2017.04.015. 21 
59.  Gallagher C, Elliott AD, Wong CX, et al. Integrated care in atrial fibrillation: A 22 
systematic review and meta-analysis. Heart 2017;103(24):1947-1953. 23 
doi:10.1136/heartjnl-2016-310952. 24 
60.  Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Improved Outcomes 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 33
by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the 1 
Simple ABC (Atrial Fibrillation Better Care) Pathway. Am. J. Med. 2018. 2 
doi:10.1016/j.amjmed.2018.06.012. 3 
61.  Pastori D, Pignatelli P, Menichelli D, Violi F, Lip GYH. Integrated Care 4 
Management of Patients With Atrial Fibrillation and Risk of Cardiovascular 5 
Events. Mayo Clin. Proc. 2018. doi:10.1016/j.mayocp.2018.10.022. 6 
62.  Pastori D, Farcomeni A, Pignatelli P, Violi F, Lip GY. ABC (Atrial fibrillation 7 
Better Care) pathway and healthcare costs in atrial fibrillation. The ATHERO-8 
AF study. Am. J. Med. 2019;0(0). doi:10.1016/j.amjmed.2019.01.003. 9 
63.  Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the 10 
Canadian Cardiovascular Society atrial fibrillation guidelines: 11 
recommendations for stroke prevention and rate/rhythm control. Can. J. 12 
Cardiol. 2012;28(2):125-36. doi:10.1016/j.cjca.2012.01.021. 13 
64.  Anandasundaram B, Lane DA, Apostolakis S, Lip GYH. The impact of 14 
atherosclerotic vascular disease in predicting a stroke, thromboembolism and 15 
mortality in atrial fibrillation patients: a systematic review. J. Thromb. Haemost. 16 
2013;11(5):975-87. doi:10.1111/jth.12177. 17 
65.  Steensig K, Olesen KKW, Thim T, et al. Coronary artery disease is 18 
independent risk factor for stroke among patients with atrial fibrillation. J. Am. 19 
Coll. Cardiol. 2018. doi:10.1016/j.jacc.2018.08.1046. 20 
66.  Steensig K, Olesen KKW, Thim T, et al. Should the Presence or Extent of 21 
Coronary Artery Disease be Quantified in the CHA2DS2-VASc Score in Atrial 22 
Fibrillation? A Report from the Western Denmark Heart Registry. Thromb. 23 
Haemost. 2018;118(12):2162-2170. doi:10.1055/s-0038-1675401. 24 
 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 34
  1 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 35
FIGURE LEGENDS 1 
 2 
Figure 1: Proportion of Papers Related to Atrial Fi brillation in PubMed from 3 
Inception to 2017 4 
Legend: AF= Atrial Fibrillation 5 
 6 
Figure 2: The ‘Birmingham 3-Step’ Management Strate gy for Anticoagulation in 7 
Patients with Atrial Fibrillation 8 
Legend: NOAC= Non-vitamin K Antagonist Oral Anticoagulant; OAC= Oral 9 
Anticoagulant; TTR= Time in Therapeutic Range; VKA= Vitamin K Antagonist. 10 
 11 
Figure 3: Atrial Fibrillation Better Care (ABC) Pat hway for Integrated Care in 12 
Atrial Fibrillation Patients  13 
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Table 1:  Summary of General Characteristics and Definitions of Contemporary Atrial Fibrillation Guidelines                                                        1 
 2 
  3 
 CCS ESC APHRS 
Year 2016 2016 2017 
Primary Source  CJC 2016; 32 (10)13 EHJ 2016; 37 (38)14 J Arrhythmia 2017; 33 (4)15 
Guidelines Methodology  Systematic search according to 
PICO; 
GRADE rating of evidence 
Systematic search according to 
PICOT; 
Experts plenary discussion 
Expert Consensus Review 
Strength of Recommendations  Strong, Conditional, Weak Classes I-IIa-IIb-III Not explicitly assessed 
Quality of Evidence  High, Moderate, Low, Very Low Level A-B-C Not explicitly assessed 
Conflict of Interest Process  Not Reported Detailed disclosure of all real or 
potential sources of COI publicly 
available 
Reported in acknowledgment 
Classification of AF  New onset, paroxysmal, persistent or 
permanent 
First diagnosed, paroxysmal, 
persistent, long-standing persistent, 
permanent 
Not explicit 
Evaluation of Valvular Origin  Rheumatic mitral stenosis, mitral 
valve repair, mechanical or bio- 
prosthetic heart valve 
Rheumatic valvular disease 
(predominantly mitral stenosis) 
or mechanical heart valves 
Not explicitly assessed 
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Table 1 (continued):  Summary of General Characteristics and Definitions of Contemporary Atrial Fibrillation Guidelines 1 
 NHFA/CSANZ ACCP CCS KHRS 
Year 2018 2018 2018 2018 
Primary Source  HLC 2018; 27 (10)16 Chest 2018;154 (5)17 CJC 2018; 34 (11)18 KCJ 2018; 48 (12)19 
Guidelines Methodology  Systematic search 
according to Clinical 
Questions; 
GRADE rating of evidence 
Systematic search 
according to PICO-guided 
Clinical Questions; 
GRADE rating of evidence 
Systematic search 
according to PICO; 
GRADE rating of evidence 
Expert Consensus Review 
Strength of Recommendations  Strong, Weak Strong, Weak Strong, Conditional, Weak Classes I-IIa-IIb-III 
Quality of Evidence  High, Moderate, Low High, Moderate, Low, Very 
Low 
High, Moderate, Low, Very 
Low 
Level A-B-C 
Conflict of Interest Process  Direct or indirect 
relationship to any third 
party, both financial and 
non-financial 
Central COIs review. If 
manageable potential COI, 
voting on relevant issues 
was prohibited 
Not Reported Reported in 
acknowledgment 
Classification of AF  Paroxysmal, persistent, 
long-standing persistent, 
permanent 
Paroxysmal, persistent, 
long-standing persistent, 
permanent 
New onset, paroxysmal, 
persistent or permanent 
Not explicit 
Evaluation of Valvular Origin  Moderate to severe 
mitral stenosis or 
mechanical heart valve 
Moderate to severe 
mitral stenosis or 
mechanical heart valve 
Rheumatic mitral stenosis, 
moderate-severe 
nonrheumatic mitral 
stenosis, or a mechanical 
heart valve 
Not explicitly assessed 
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Legend:  APHRS= Asia Pacific Heart Rhythm Society; CCS= Canadian Cardiovascular Society; CJC= Canadian Journal of 1 
Cardiology; COI= Conflict of Interest; CSANZ= Cardiac Society of Australia and New Zealand; EHJ= European Heart Journal; 2 
ESC= European Society of Cardiology; GRADE= Grading of Recommendations, Assessment, Development and Evaluation; HLC= 3 
Heart, Lung and Circulation; KCJ= Korean Circulation Journal; NHFA= National Heart Foundation of Australia; PICO(T)= 4 
Population, Intervention, Comparison, Outcome, (Time). 5 
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Table 2:  Baseline Thromboembolic Risk Evaluation and Oral Anticoagulation Prescription Algorithm 1 
  2 
 CCS ESC APHRS 
Year 2016 2016 2017 
Thromboembolic 
Risk Assessment 
CHADS-65 
(‘CCS Algorithm’) 
CHA2DS2-VASc CHA2DS2-VASc 
Rating of Evidence  Strong Recommendation,  
High-Quality Evidence 
Class I, Level A Not rated 
OAC Prescription 
Algorithm 
i) OAC should be considered for all 
patients ≥65 years old or with ≥1 
CHADS2 risk factors. 
ii) <65 years old and with arterial 
disease ASA should be considered 
i) OAC is indicated in all patients with a 
CHA2DS2-VASc ≥2, excluding sex 
category 
ii) OAC should be considered in all 
patients with just 1 CHA2DS2-VASc risk 
factors, excluding sex category 
OAC is indicated in all patients with a 
CHA2DS2-VASc ≥1, excluding sex 
category 
Rating of Evidence  i) Strong Recommendation,  
Moderate-Quality Evidence 
ii) Conditional Recommendation, 
Moderate-Quality Evidence 
i) Class I, Level A 
ii) Class IIa, Level B 
Not rated 
Use of NOACs  A NOAC is preferred over VKA A NOAC is preferred over VKA A NOAC is preferred over VKA 
Rating of Evidence  Strong Recommendation,  
High-Quality Evidence 
Class I, Level A Not rated 
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Table 2 (continued):  Baseline Thromboembolic Risk Evaluation and Oral Anticoagulation Prescription Algorithm 1 
Legend:  ASA= Acetylsalicylic acid; CHADS= Congestive Heart Failure, Hypertension, Age, Diabetes Mellitus, Stroke/Transient 2 
Ischemic Attack; CHA2DS2-VASc= Congestive Heart Failure, Hypertension, Age≥75 years, Diabetes Mellitus, Stroke/Transient 3 
 NHFA/CSANZ ACCP CCS KHRS 
Year 2018 2018 2018 2018 
Thromboembolic 
Risk Assessment 
CHA2DS2-VA CHA2DS2-VASc CHADS-65 
(‘CCS Algorithm’) 
CHA2DS2-VASc 
Rating of Evidence  Strong Recommendation, 
Moderate-Quality Evidence 
Strong Recommendation, 
Moderate-Quality Evidence 
Strong Recommendation,  
High-Quality Evidence (2014) 
Class I, Level A 
OAC Prescription 
Algorithm 
i) OAC is indicated in all patients  
with CHA2DS2-VA ≥2 
ii) OAC should be considered in 
all patients with CHA2DS2-VA 1 
OAC is indicated in all patients 
with a CHA2DS2-VASc ≥1, 
excluding sex category 
 
i) OAC should be considered for 
all patients ≥65 years old or 
with ≥1 CHADS2 risk factors. 
ii) <65 years old and with arterial 
disease ASA should be 
considered 
i) OAC is indicated in all patients 
with a CHA2DS2-VASc ≥2, 
excluding sex category 
ii) OAC should be considered in all 
patients with just 1 CHA2DS2-
VASc risk factors, excluding sex 
category 
Rating of Evidence  i) Strong Recommendation, 
High-Quality Evidence 
ii) Strong Recommendation, 
Moderate-Quality Evidence 
Strong Recommendation, 
Moderate-Quality Evidence 
i) Strong Recommendation,  
Moderate-Quality Evidence 
ii) Conditional Recommendation, 
Moderate-Quality Evidence (2014) 
i) Class I, Level A 
ii) Class IIa, Level B 
Use of NOACs  A NOAC is preferred over VKA A NOAC is preferred over VKA A NOAC is preferred over VKA A NOAC is preferred over VKA 
Rating of Evidence  Strong Recommendation, 
Moderate-Quality Evidence 
Strong Recommendation, 
Moderate-Quality Evidence 
Strong Recommendation, 
High-Quality Evidence (2014) 
Class I, Level A 
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Ischemic Attack, Vascular Disease, Age 65-74 years, Sex category; NOAC= Non-vitamin K antagonist oral anticoagulant; OAC= 1 
Oral anticoagulant; VKA= Vitamin K Antagonist; for other acronyms please see Table 1 legend. 2 
  3 
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Table 3:  Baseline Bleeding Risk Evaluation and Associated Recommendations 1 
 2 
  3 
 CCS ESC APHRS 
Year 2016 2016 2017 
Bleeding Risk 
Assessment 
HAS-BLED Use of clinical risk scores to evaluate 
modifiable and potentially modifiable risk 
factors for major bleeding 
HAS-BLED 
Rating of Evidence  Strong Recommendation, 
High-Quality Evidence (2010) 
Class IIa, Level B Not rated 
Associated 
Recommendation 
Adopt specific measures to mitigate 
bleeding risk factors 
Not withhold OAC. Identify and correct 
modifiable bleeding risk factors 
For patients with HAS-BLED ≥3 not 
withhold OAC and provide regular review 
and follow-up of the modifiable bleeding 
risk factors. 
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Table 3 (continued):  Baseline Bleeding Risk Evaluation and Associated Recommendations 1 
Legend:  HAS-BLED= Hypertension, Abnormal renal/liver function, Stroke, Bleeding, Labile anticoagulation quality, Elderly, Drugs 2 
or alcohol; for other acronyms please see previous tables legends. 3 
  4 
 NHFA/CSANZ ACCP CCS KHRS 
Year 2018 2018 2018 2018 
Bleeding Risk 
Assessment 
Identification of reversible bleeding 
risk factors 
HAS-BLED HAS-BLED HAS-BLED 
Rating of Evidence  Strong Recommendation, 
Low-Quality of Evidence 
Strong Recommendation, 
Moderate-Quality of Evidence 
Strong Recommendation, 
High-Quality Evidence (2010) 
Class I, Level A 
Associated 
Recommendation 
Minimisation of bleeding risk 
through treating of reversible risk 
factors 
HAS-BLED ≥3 should not be a 
reason to withhold OAC. 
Those patients at higher 
bleeding risk is warranted for 
more frequent and regular 
reviews and follow-up 
Adopt specific measures to mitigate 
bleeding risk factors 
A high bleeding risk is not a reason 
to withhold OAC treatment. 
Modifiable bleeding risk factors 
should be addressed to reduce 
bleeding risk 
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Table 4:  Combination of OAC with Antiplatelet Drugs in patients with Concomitant Cardiac Disease 1 
 CCS ESC APHRS 
Year 2016 2016 2017 
Patients with ACS  i) In patients <65 years old and no 
CHADS2 risk factors 12 months treatment 
with aspirin and P2Y12 inhibitor (chosen 
according to risk and implementation of 
PCI) with indefinite treatment with aspirin 
if PCI has been performed 
ii) In patients ≥65 years old and CHADS2 
≥1 and no PCI is undertaken clopidogrel 
75 mg and OAC for 12 months followed 
by only OAC 
iii) In patients ≥65 years old and CHADS2 
≥1 and PCI is undertaken ASA 81 mg + 
clopidogrel 75 mg + OAC for 3/6 months 
(according to risk) followed by clopidogrel 
75 mg + OAC up to 12 months then OAC 
i) In patients not undergoing PCI dual 
therapy with OAC and aspirin or 
clopidogrel should be considered up to 12 
months 
ii) In patients undergoing PCI triple 
therapy with OAC, aspirin and clopidogrel 
should be considered from 1 to 6 months 
on the basis of bleeding risk, followed by 
dual therapy with aspirin or clopidogrel 
iii) Duration of combination therapy, 
especially triple therapy, should be kept 
to the minimum, balancing risk of 
bleeding and recurrent events 
 
In patients with ACS triple therapy can be 
continued from 1 to 6 months according 
to bleeding risk (high or low) with dual 
therapy up to 12 months after the event 
Rating of Evidence  i) Strong Recommendation, 
High-Quality Evidence 
ii) Conditional Recommendation, 
Low-Quality Evidence 
iii) Conditional Recommendation, 
Low-Quality Evidence 
i) Class IIa, Level C 
ii) Class IIa, Level C 
iii) Class IIa, Level B 
Not rated 
Elective PCI  i) In patients <65 years and no CHADS2 i) In patients undergoing elective PCI, use In patients with elective PCI triple therapy 
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 1 
  2 
risk factors indefinite treatment with 
aspirin + 12 months of treatment with 
clopidogrel is recommended 
ii) In patients ≥65 and CHADS2 risk 
factors OAC + clopidogrel with no aspirin 
are indicated for 12 months followed by 
indefinite OAC 
of triple therapy with OAC, aspirin and 
clopidogrel should be limited to 1 month 
ii) Dual therapy with OAC and aspirin or 
clopidogrel, could be continued up to 6 or 
12 months according to bleeding risk 
should be continued for 1 month, with 
dual therapy continued up to 6 or 12 
months, according to bleeding risk (high 
or low) 
Rating of Evidence  i) Strong Recommendation, 
High-Quality Evidence 
ii) Strong Recommendation, 
High-Quality Evidence 
i) Class IIa, Level B 
ii) Class IIa, Level C 
Not rated 
Use of NOACs  When OAC indicated a NOAC is 
preferred over warfarin 
When NOAC is used the lowest 
recommended dose should be 
administered together with antiplatelet 
therapy 
A NOAC is preferred over warfarin 
Rating of Evidence  Not rated Not rated Not rated 
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Table 4 (continued):  Combination of OAC with Antiplatelet Drugs in patients with Concomitant Cardiac Disease 1 
 NHFA/CSANZ ACCP CCS KHRS 
Year 2018 2018 2018 2018 
Patients with ACS  i) In patients with ACS or PCI 
duration of triple therapy 
should be kept as short as 
possible to minimize risk of 
bleeding, still ensuring the 
coverage of the high risk of 
recurrent event/stent 
thrombosis 
ii) After triple therapy, dual 
therapy with OAC and aspirin 
100 mg or clopidogrel 75 mg is 
recommended 
i) In patients with ACS and low 
bleeding risk, triple therapy is 
suggested up to 6 months, followed by 
OAC plus single antiplatelet 
(preferably clopidogrel) up to 12 
months 
ii) In patients with ACS and high 
bleeding risk, triple therapy is 
suggested from 1 to 3 months, 
followed by OAC plus antiplatelet 
(preferably clopidogrel) up to 12 
months 
iii) In patients with very high bleeding 
risk, a strategy with OAC and single 
antiplatelet (preferably clopidogrel) for 
6-9 months is suggested 
i) In patients ≤65 years and no 
CHADS2, use of antiplatelet 
therapy according to 
characteristics and extent of 
disease as directed by other 
guidelines 
ii) In patients ≥65 years and 
CHADS2 ≥1 not undergoing PCI, 
OAC plus P2Y12 inhibitor 
(preferably clopidogrel) is 
indicated for 12 months 
iii) In patients ≥65 years and 
CHADS2 ≥1 undergoing PCI, 
OAC, aspirin and clopidogrel are 
indicated up to 6 months, 
followed by OAC plus clopidogrel 
up to 12 months 
No recommendation 
Rating of 
Evidence 
i) Strong Recommendation,  
Moderate-Quality of Evidence 
ii) Strong Recommendation, 
Low-Quality of Evidence 
i) Weak Recommendation, 
Low-Quality of Evidence 
ii) Weak Recommendation, 
Low-Quality of Evidence 
iii) Weak Recommendation, 
i) Not rated 
ii)  Weak Recommendation, 
Low-Quality of Evidence 
iii) Weak Recommendation, 
Moderate-Quality of Evidence 
- 
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Low-Quality of Evidence  
Elective PCI  i) In patients with ACS or PCI 
duration of triple therapy 
should be kept as short as 
possible to minimize risk of 
bleeding, still ensuring the 
coverage of the high risk of 
recurrent event/stent 
thrombosis 
ii) After triple therapy, dual 
therapy with OAC and aspirin 
100 mg or clopidogrel 75 mg is 
recommended 
i) In patients receiving PCI and low 
bleeding risk, triple therapy is 
suggested for 1 month, followed by 
OAC plus single antiplatelet 
(preferably clopidogrel) up to 12 
months 
ii) In patients receiving PCI and high 
bleeding risk, triple therapy is 
suggested for 1 month, followed by 
OAC plus antiplatelet (preferably 
clopidogrel) up to 6 months 
iii) In patients with very high 
bleeding risk, a strategy with OAC 
and single antiplatelet (preferably 
clopidogrel) for 6 months is 
suggested 
i) In patients ≥65 years and 
CHADS2 ≥1 receiving PCI without 
high-risk features, OAC plus 
clopidogrel is suggested for at 
least 1 month (BMS) or at least 3 
months 
ii) In patients ≥65 years and 
CHADS2 ≥1 receiving PCI with 
high-risk features, OAC, aspirin 
and clopidogrel are indicated up 
to 6 months, followed by OAC 
plus clopidogrel up to 12 months 
Triple therapy is recommended to 
be as short as possible, in relation 
to bleeding risk, unless the risk of 
stent thrombosis/recurrence would 
not be too high. After triple therapy, 
dual therapy with OAC and P2Y12 
inhibitor (preferably clopidogrel) 
should be continued up to 12 
months after PCI. 
Rating of 
Evidence 
i) Strong Recommendation, 
Moderate-Quality of Evidence 
ii) Strong Recommendation, 
Low-Quality of Evidence 
i) Weak Recommendation, 
Low-Quality of Evidence 
ii) Weak Recommendation, 
Low-Quality of Evidence 
iii) Weak Recommendation, 
Low-Quality of Evidence 
i) Weak Recommendation, 
Moderate-Quality of Evidence 
ii) Weak Recommendation, 
Moderate-Quality of Evidence 
 
Not rated 
Use of NOACs  No specific recommendation 
done. 
NOACs are indicated equally to VKAs A NOAC is preferred over VKA A NOAC is preferred over VKA 
Rating of - Weak Recommendation, Weak Recommendation, Not rated 
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Legend:  ACS= Acute Coronary Syndrome; PCI= Percutaneous Coronary Intervention; for other acronyms please see previous 1 
tables legends. 2 
  3 
Evidence  Low-Quality of Evidence Moderate-Quality of Evidence 
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Table 5:  Oral Anticoagulation Management in Patients Undergoing Ablation or Cardioversion Procedure 1 
 CCS ESC APHRS 
Year 2016 2016 2017 
Ablation Procedure  OAC should be continued after AF 
surgical ablation according to CCS 
algorithm 
i) All patients should receive OAC for at 
least 8 weeks after catheter ablation 
ii) OAC should be continued indefinitely 
after successful catheter ablation in 
patients at high risk of stroke 
iii) Continuation of OAC with VKAs or 
NOACs during procedure is 
recommended 
 
i) NOACs can be safe and effective 
alternatives to VKAs for periprocedural 
anticoagulation 
ii) OAC should be continued for at least 3 
weeks before procedure in patients with 
at least 48 H of AF 
iii) OAC should be continued for at least 2 
months after ablation, and longer in those 
patients with high risk of stroke 
Rating of Evidence  Strong Recommendation, 
Moderate-Quality of Evidence 
i) Class IIa, Level B 
ii) Class IIb, Level C 
iii) Class IIb, Level B (VKAs) or Level C 
(NOACs) 
Not rated 
Cardioversion 
Procedure 
OAC should be prescribed for 3 weeks 
before cardioversion and at least 4 weeks 
after. If AF recurs OAC should be 
prescribed on the basis of the CCS 
algorithm. If SR is achieved, decision on 
continuing OAC after 4 weeks of 
treatment should be based on risk of 
stroke and upon expert consultation 
i) Effective anticoagulation is 
recommended for at least 3 weeks before 
cardioversion 
ii) Anticoagulation with heparin or NOAC 
should be initiated before every 
cardioversion procedure 
iii) In patients without stroke risk factors 
anticoagulation is recommended for 4 
weeks. In those at risk of stroke 
anticoagulation should be continued long-
term after procedure 
iv) Perform TEE is recommended as an 
alternative to OAC  
v) If with TEE a thrombus is identified 3 
i) Anticoagulation is needed 3 weeks 
before and 4 weeks after cardioversion 
procedure 
ii) In patients undergoing TEE, if 
thrombus is identified OAC is needed for 
at least 4 weeks and repeat TEE to 
ensure thrombus resolution 
ii) After cardioversion long-term OAC is 
needed in patients with high risk of stroke 
iv) For OAC in patients undergoing 
cardioversion both VKAs and NOACs can 
be considered 
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 1 
  2 
weeks OAC is recommended 
Rating of Evidence  Strong Recommendation, 
Moderate-Quality of Evidence 
i) Class I, Level B 
ii) Class IIa, Level B 
iii) Class I, Level B 
iv) Class I, Level B 
v) Class I, Level C 
Not rated 
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Table 5 (continued):  Oral Anticoagulation Management in Patients Undergoing Ablation or Cardioversion Procedure 1 
 NHFA/CSANZ ACCP CCS KHRS 
Year 2018 2018 2018 2018 
Ablation 
Procedure 
Uninterrupted OAC is 
recommended for patients 
undergoing catheter ablation 
i) OAC with VKA, dabigatran or 
rivaroxaban is recommended for 
patients undergoing ablation 
ii) After ablation long-term OAC should 
be prescribed on the basis of 
thromboembolic risk profile 
Use of uninterrupted OAC, either 
with NOACs or VKAs is 
recommended 
i) Uninterrupted OAC is 
recommended for patients 
undergoing catheter ablation 
ii) OAC after ablation should be 
continued for at least 2 months 
iii) After 2 months, long-term OAC 
should be decided on patient’s 
stroke risk 
Rating of 
Evidence 
Strong Recommendation, 
Moderate-Quality of Evidence 
i) Weak Recommendation, 
Low-Quality of Evidence 
ii) Weak Recommendation, 
Low-Quality of Evidence 
Weak Recommendation, 
Moderate-Quality of Evidence 
Not rated 
Cardioversion 
Procedure 
i) OAC for 3 weeks is 
recommended (or TEE to 
document absence of left 
atrium thrombus) before 
cardioversion procedure 
ii) OAC is recommended for at 
least 4 weeks after 
cardioversion procedure 
i) In patients with AF for 48H or more 
OAC with VKAs or NOACs is 
recommended at least 3 weeks before 
cardioversion or TEE approach with 
abbreviated OAC treatment 
ii) In patients with 48H or less AF or 
hemodynamic instability, parenteral 
anticoagulation should be started as 
soon as possible before procedure 
and continued for at least 4 weeks  
i) Patients planned to receive 
cardioversion should receive 
OAC for 3 weeks before 
procedure 
ii) 3 weeks OAC treatment can be 
waived if AF is <12 with no recent 
stroke or within 12 and 48 hours 
and there is no substantial stroke 
risk 
iii)  OAC is recommended to be 
i) OAC is recommended for at least 
3 weeks before cardioversion 
ii) After procedure OAC is 
recommended for at least for 4 
weeks in patients without stroke risk 
factors. In patients at risk of stroke, 
long-term OAC is recommended 
iii) Anticoagulation with heparin or 
NOAC should be initiated as soon 
as possible before every 
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Legend:  SR= Sinus Rhythm; TEE= Trans-Esophageal Echocardiography; for other acronyms please see previous tables legends. 1 
 2 
iii) After cardioversion, OAC with 
VKAs or NOACs should be continued 
for at least 4 weeks. Continuing OAC 
beyond 4 weeks should be based on 
general OAC prescription decision 
making 
continued for at least 4 weeks 
iv) TEE can be considered as an 
alternative to OAC 
v) Both NOACs and 
heparin/VKAs strategies can be 
used 
vi) OAC continuation after 4 
weeks should be decided on the 
basis of CCS algorithm 
cardioversion procedure 
iv) If a TEE identify a thrombus in 
left atrium, effective anticoagulation 
is recommended for at least 3 
weeks 
Rating  of 
Evidence 
i) Strong Recommendation, 
Low-Quality of Evidence 
i) Strong Recommendation, 
Moderate-Quality of Evidence 
ii) Weak Recommendation, 
Low-Quality of Evidence 
iii) Strong Recommendation, 
Moderate-Quality of Evidence 
i) Strong Recommendation, 
Moderate-Quality of Evidence 
ii) Weak Recommendation, 
Low-Quality of Evidence 
iii) Weak Recommendation, 
Low-Quality of Evidence 
iv)  Weak Recommendation, 
Moderate-Quality of Evidence 
v) Weak Recommendation, 
Low-Quality of Evidence 
vi) Strong Recommendation, 
Moderate-Quality of Evidence 
i) Class I, Level B 
ii) Class I, Level B 
iii) Class IIa, Level B 
iv) Class I, Level C 
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